Too many vessels? Not enough? The wrong kind? The VEGF debate continues

Nature Medicine

Volumn 7, Issue 4, 2001, Pages 403-404

  Ware, J A ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR;

ANGIOGENESIS; ATHEROSCLEROSIS; CIRCULATION; ISCHEMIA; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; REVASCULARIZATION; SHORT SURVEY;

ANIMALS; ARTERIOSCLEROSIS; CLINICAL TRIALS; ENDOTHELIAL GROWTH FACTORS; HUMANS; LYMPHOKINES; MYOCARDIAL ISCHEMIA; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; SAFETY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0035048967     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/86452     Document Type: Short Survey

References (9)

1. Angiogenesis in ischemic heart disease
2. Vascular endothelial growth factor enhances atherosclerotic plaque progression
3. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: Results of a phase I randomized double blind placebo controlled trial
4. The VIVA trial: One year follow up
5. Angiogenesis in atherosclerosis and restenosis
6. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice
7. Hypothesis: Vasa vasorum and neovascularization of human coronary arteries; a possible role in the pathophysiology of atherosclerosis
8. Bone marrow derived endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization
9. Clinical trials in coronary angiogenesis: Issues, problems, consensus